Little information is available regarding whether an unrelated cord blood (UCB) unit or a related donor with a 1-antigen mismatch at the HLA-A, HLA-B or HLA-DR locus in the graft-versus-host direction (RD/1AG-MM-GVH) should be selected as an alternative donor for patients without an HLA-matched related/unrelated donor. Therefore, we conducted a retrospective study using national registry data on patients with leukemia or myelodysplastic syndrome who received transplantation using a single UCB (n ¼ 2288) unit or an RD/1AG-MM-GVH (n ¼ 525). We found that the survival rate in the UCB group was comparable to that in the RD/1AG-MM-GVH group, although the RD/1AG-MM-GVH group with an HLA-B mismatch showed significantly higher overall and non-relapse mortality. Neutrophil and platelet engraftment were significantly faster, whereas the incidence of acute or chronic graft-versus-host disease (GVHD) was significantly higher in the RD/1AG-MM-GVH group. The incidence of acute or chronic GVHD in the RD/1AG-MM-GVH group with in vivo T-cell depletion was comparable to that in the UCB group, which translated into a trend toward better overall survival, regardless of the presence of an HLA-B mismatch. In conclusion, UCB and RD/1AG-MM-GVH are comparable for use as an alternative donor, except for RD/1AG-MM-GVH involving an HLA-B mismatch.
INTRODUCTION
For patients who lack an HLA-identical sibling, an HLA-matched unrelated donor (MUD) is considered to be the preferred alternative donor in allogeneic hematopoietic cell transplantation (HCT). [1] [2] [3] [4] [5] However, it is difficult to find an MUD for patients with rare HLA haplotypes. Furthermore, it takes at least a few months from the start of an unrelated donor search to actually receive a graft. Therefore, there is a large demand for an alternative source to an HLA-identical sibling or MUD, particularly for patients who have a rare haplotype or who need immediate transplantation.
Unrelated cord blood (UCB) has emerged as a promising alternative source for pediatric and adult patients. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] In UCB transplantation, up to two antigen/allele mismatches between a recipient and cord blood unit are acceptable without an increased risk of acute graft-versus-host disease (GVHD). The clinical outcome in UCB transplantation is improving, and is almost comparable to that in HLA 8/8 allele MUD transplantation, although a high risk of graft failure and early treatment-related complications are still major issues. [15] [16] [17] Another alternative source is an HLA-mismatched related donor, particularly when a related donor with a 1-antigen mismatch at the HLA-A, HLA-B, or HLA-DR locus in the graft-versus-host (GVH) direction (RD/1AG-MM-GVH) is available. HCT from an RD/1AG-MM-GVH results in a higher but acceptable incidence of acute GVHD. [18] [19] [20] In previous studies, HLA mismatches in the host-versusgraft (HVG) direction were associated with a higher incidence of graft failure and lower overall survival (OS). 18, 19, 21 However, the risk of graft failure might have been improved by the use of conditioning regimens that strongly suppress the recipient's immune system. 22 Therefore, in current clinical practice in Japan, stem cell transplantation from an RD/1AG-MM-GVH is being performed while accepting multiple antigen mismatches in the HVG direction without specific ex vivo stem cell manipulation. 18, 19, 23 We have recently reported that OS in transplantation from an RD/1AG-MM-GVH involving an HLA-B antigen mismatch was inferior, whereas that from an RD/1AG-MM-GVH involving an HLA-A or -DR antigen mismatch was comparable to that from an 8/8-MUD in standardrisk diseases. 23 Unlike transplantation from an MUD, transplantation using a UCB unit or an RD/1AG-MM-GVH can be performed immediately when necessary. However, little information is available regarding the priority in selecting these alternative donors. Therefore, we conducted a retrospective study using national registry data on 2813 patients with leukemia or myelodysplastic syndrome (MDS) who received transplantation using a single UCB or an RD/ 1AG-MM-GVH.
MATERIALS AND METHODS

Data collection
Data for patients (age: X16 years) with acute myeloid leukemia, acute lymphoblastic leukemia, MDS and chronic myelogenous leukemia who received a first HCT using a single HLA 0-2 antigen-mismatched UCB unit or an RD/1AG-MM-GVH between 1 January 1998 and 31 December 2009 were obtained from the Transplant Registry Unified Management Program (TRUMP), 24 which includes data from the Japan Cord Blood Bank Network (JCBBN) and the Japan Society for Hematopoietic Cell Transplantation (JSHCT). Our analysis included 2306 patients who received a single UCB graft (UCB group) and 541 patients who received a graft from an RD/ 1AG-MM-GVH (RD/1AG-MM-GVH group). As of January 2012, double UCB grafts for HCT are not available in Japan. The following patients were excluded: 26 patients who lacked data on survival status, survival date, sex of recipient, or GVHD prophylaxis and 8 patients who received stem cells that had been manipulated by ex vivo T-cell depletion or CD34 selection. Overall, 2288 patients who received a UCB unit and 525 who received a graft from an RD/1AG-MM-GVH fulfilled the criteria. The study was approved by the data management committees of TRUMP and by the institutional review boards of Japanese Red Cross Nagoya First Hospital and Saitama Medical Center, Jichi Medical University, where this study was organized.
Histocompatibility
Histocompatibility data for the HLA-A, HLA-B and HLA-DR loci were obtained from reports from the institution where the transplantation was performed or from cord blood banks. To reflect current practice in Japan, HLA matching in UCB or RD/1AG-MM-GVH transplantation was assessed by serological data for HLA-A, HLA-B, and HLA-DR loci. An HLA mismatch in the GVH direction was defined as when the recipient's antigens or alleles were not shared by the donor, whereas a mismatch in the HVG direction was defined as when the donor's antigens or alleles were not shared by the recipient.
End points
The primary end point of the study was to compare OS rates between the UCB and RD/1AG-MM-GVH groups. Other end points were the cumulative incidences of neutrophil and platelet engraftment, acute and chronic GVHD, relapse, and non-relapse mortality (NRM). Neutrophil recovery was considered to have occurred when the absolute neutrophil count exceeded 0.5 Â 10 9 /l for 3 consecutive days following transplantation. Platelet recovery was considered to have occurred when the absolute platelet count exceeded 50 Â 10 9 /l without platelet transfusion. The physicians who performed transplantation at each center diagnosed and graded acute and chronic GVHD according to the traditional criteria. 25, 26 The incidence of chronic GVHD was evaluated in patients who survived for at least 100 days.
Statistical analysis
Descriptive statistics were used to summarize variables related to the patient characteristics. Comparisons between groups were performed with the w 2 -test or extended Fisher's exact test as appropriate for categorical variables and the Mann-Whitney U-test for continuous variables. The probability of OS was estimated according to the Kaplan-Meier method, and the groups were compared with the log-rank test. The adjusted probability of OS was estimated according to the Cox proportional-hazards model, with other significant variables considered in the final multivariate model. The probabilities of neutrophil and platelet engraftment, acute and chronic GVHD, NRM, and relapse were estimated on the basis of cumulative incidence methods, and the groups were compared with the Gray test; 27, 28 competing events were death without engraftment for neutrophil and platelet engraftment, death or relapse without GVHD for acute and chronic GVHD, death without relapse for relapse, and relapse for NRM. The Cox proportional-hazards model was used to evaluate variables that may affect OS, whereas the Fine and Gray proportionalhazards model was used to evaluate variables that may affect engraftment, GVHD, NRM and relapse. 29 We classified the conditioning regimen as myeloablative if either total body irradiation 48 Gy, oral busulfan X9 mg/kg, intravenous busulfan X7.2 mg/kg, or melphalan 4140 mg/m 2 was used in the conditioning regimen, and otherwise classified it as reduced intensity, based on the report by the Center for International Blood and Marrow Transplant Research. 30 For patients for whom the doses of agents used in the conditioning regimen were not available, we used the information on conditioning intensity (myeloablative or reduced intensity) reported by the treating clinicians. Acute leukemia in the first or second remission, chronic myelogenous leukemia in the first or second chronic phase or accelerated phase, and MDS with refractory anemia or refractory anemia with ringed sideroblasts were defined as standard-risk diseases, and other conditions were defined as high-risk diseases. The following variables were considered when comparing the UCB and RD/1AG-MM-GVH groups: the recipient's age group (p50 years or 450 years at transplantation), sex of recipient, disease (acute myeloid leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia or MDS), disease status before transplantation (standard-or high-risk), type of conditioning regimen (myeloablative or reduced intensity), type of GVHD prophylaxis (calcineurin inhibitor and methotrexate, calcineurin inhibitor only, or other), year of transplantation (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) , and the time from diagnosis to transplantation (o6 months or X6 months). In the analysis within the RD/1AG-MM-GVH group, the use of in vivo T cell depletion (no vs yes), stem cell source (peripheral blood (PB) stem cells vs bone marrow (BM)), and the number of HLA mismatches in the HVG direction (0-1 vs 2-3) were also considered. Factors without a variable of main interest were selected in a stepwise manner from the model with a variable retention criterion of Po0.05. We then added a variable of main interest to the final model. All tests were two-sided, and Po0.05 was considered to indicate statistical significance. All statistical analyses were performed with Stata version 12 (Stata Corp., College Station, TX, USA) and EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan). 31 EZR is a graphical user interface for R (The R Foundation for Statistical Computing, version 2.13.0, Vienna, Austria). More precisely, it is a modified version of R commander (version 1.6-3) that was designed to add statistical functions that are frequently used in biostatistics. Table 1 shows the patient and transplant characteristics. Recipients of an RD/1AG-MM-GVH were younger than recipients of a UCB unit. Approximately half of the recipients in the RD/1AG-MM-GVH group received PB. The number of HLA mismatches in the GVH direction between a UCB unit and recipient was 0 in 10%, 1 in 33% and 2 in 57%. In the RD/1AG-MM-GVH group, the number of antigen mismatches in the HVG direction was 0 in 12%, 1 in 68%, 2 in 18% and 3 in 3%. Most of the recipients of an RD/1AG-MM-GVH received a calcineurin inhibitor with methotrexate for GVHD prophylaxis, whereas 25% of UCB recipients received only calcineurin inhibitor. In vivo T-cell depletion including antithymocyte globulin (ATG) or alemtuzumab was used in 10% of the RD/1AG-MM-GVH group, but in only 1% of the UCB group. Alemtuzumab was used in only one patient, who received transplantation from an RD/1AG-MM-GVH. Information regarding the dose and type of ATG was missing in two-third of the patients who received ATG. Available data showed that the median dose of thymoglobulin was 2.5 (range 2.5-9.0, n ¼ 9) and 2. Neutrophil and platelet engraftment The incidence of neutrophil engraftment at day 50 in the RD/1AG-MM-GVH group was higher than that in the UCB group (UCB group, 73%, 95% confidence interval (CI), 71-75%; RD/1AG-MM-GVH group, 93%, 95% CI, 91-95%; Gray test, Po0.001; Figure 1a ). The incidence of platelet engraftment at day 150 in the Transplant using UCB vs HLA 1-AG mismatched RD J Kanda et al RD/1AG-MM-GVH group was also higher than that in the UCB group (UCB group, 53%, 95% CI, 51-55%; RD/1AG-MM-GVH group, 70%, 95% CI, 66-74%; Gray test, Po0.001; Figure 1b) . The use of RD/1AG-MM-GVH was significantly associated with a higher incidence of neutrophil and platelet engraftment in the multivariate analysis (neutrophil engraftment, hazard ratio (HR), 3.46, Table 1 ).
RESULTS
Characteristics of patients and transplants
Acute and chronic GVHD The incidence of grade II-IV or grade III-IV acute GVHD in the RD/ 1AG-MM-GVH group was significantly higher than that in the UCB group (grade II-IV acute GVHD at day 100: UCB group, 34%, 95% CI, 32-36%; RD/1AG-MM-GVH group, 50%, 95% CI, 45-54%; Gray test, Po0.001; grade III-IV acute GVHD at day 100: UCB group, 11%, 95% CI, 10-13%; RD/1AG-MM-GVH group, 21%, 95% CI, 17-24%; Gray test, Po0.001; Figures 2a and b) . The incidence of chronic GVHD or extensive type of chronic GVHD in the RD/ 1AG-MM-GVH group was also significantly higher than that in the UCB group (chronic GVHD at 3 years: UCB group, 25%, 95% CI, Transplant using UCB vs HLA 1-AG mismatched RD J Kanda et al of transplantation (1998) (1999) (2000) (2001) (2002) (2003) (2004) . Figure 3a shows the adjusted survival curves of the two groups. Next, the HLA-A, HLA-B and HLA-DR mismatched groups in transplantation from an RD/1AG-MM-GVH were compared with the UCB group. The OS rate of patients who received transplantation from an RD/1AG-MM-GVH involving an HLA-B mismatch was significantly lower than that in the UCB group (P ¼ 0.043; Figure 3b and Table 2) , and a subgroup analysis revealed that the adverse effect of an HLA-B mismatch was significant only in standard-risk patients (standard-risk, P ¼ 0.023; high-risk, P ¼ 0.326; Table 2 ).
Relapse and NRM The 3-year relapse rates in the UCB and RD/1AG-MM-GVH groups were 35% (95%CI, 33-37%) and 32% (95% CI, 28-36%), respectively (Gray test; P ¼ 0.041; Figure 4a ), and a significant decrease in the incidence of relapse was found in the RD/1AG-MM-GVH group in the multivariate analysis (RD/1AG-MM-GVH vs UCB, HR, 0.78, 95%CI, 0.64-0.95, P ¼ 0.012; Table 3 ). The impact of reducing the incidence of relapse did not differ according to the HLA mismatch antigen in the RD/1AG-MM-GVH group (Table 3 and Figure 4b ). The 3-year NRM rates in the UCB and RD/1AG-MM-GVH groups were 30% (95% CI, 28-32%) and 32% (95% CI, 28-36%), respectively (Gray test; P ¼ 0.474; Figure 4c ), and a significant increase in the NRM rate was observed in the RD/1AG-MM-GVH group in the multivariate analysis (RD/1AG-MM-GVH vs UCB, HR, 1.24, 95% CI, 1.04-1.47, P ¼ 0.016; Table 3 ). In particular, the NRM rate of patients who received transplantation from an RD/1AG-MM-GVH with an HLA-B mismatch was significantly higher than that in the UCB group (RD/1AG-MM-GVH vs UCB, HR, 1.50, 95% CI, 1.17-1.92, P ¼ 0.001; Figure 4d and Table 3 ). The causes of death in patients who died without relapse are shown in Supplementary Table 3 . The rates of GVHD and organ failure in the RD/1AG-MM-GVH group were higher than those in the UCB group (GVHD, 18 vs 10%, organ failure, 28 vs 19%), whereas the rates of graft failure and infection were lower in the RD/1AG-MM-GVH group (graft failure, 1 vs 5%; infection, 26 vs 38%).
The impact of the use of in vivo T-cell depletion in the RD/1AG-MM-GVH group Based on the fact that the leading causes of death in the RD/1AG-MM-GVH group were GVHD and organ failure, we analyzed the risk factors for the development of acute GVHD in this group. Because the use of in vivo T-cell depletion significantly lowered the risk of acute GVHD, we re-compared the RD/1AG-MM-GVH group and the UCB group while focusing on the use of in vivo T-cell depletion in the RD/1AG-MM-GVH group. The incidence of grade II-IV or grade III-IV acute GVHD or chronic or extensive chronic GVHD in the RD/1AG-MM-GVH group using in vivo T-cell depletion was comparable to that in the UCB group (Supplementary Figure 1 and Supplementary Table 4) , whereas the incidences of neutrophil and platelet engraftment were significantly higher in the RD/1AG-MM-GVH group using in vivo T-cell depletion than in the UCB group (neutrophil engraftment, HR, 5.52, 95% CI, 3.36-9.05, Po0.001; platelet engraftment, HR 2.01, 95% CI, 1.26-3.21, Po0.001). Compared to the UCB group, the RD/1AG-MM-GVH group with T-cell depletion showed lower overall and NRM, albeit these differences were not significant, which suggests that the use of in vivo T-cell depletion may improve the outcome of transplantation from an RD/1AG-MM-GVH ( Figure 5, Supplementary Table 5 ). It is interesting to note that the adverse impact of an HLA-B mismatch vs HLA-A or -DR Figure 4 . Relapse and non-relapse mortality. Cumulative incidence of relapse and non-relapse mortality after transplantation using an unrelated cord blood vs a related donor with a 1-antigen mismatch at the HLA-A, HLA-B or HLA-DR locus in the GVH direction (a, c) or with an HLA-A, -B, or -DR antigen mismatch in the GVH direction (b, d) are shown. With regard to the effect of stem cell source, the incidence of acute and chronic GVHD in the RD/1AG-MM-GVH group using BM was lower than that with PB but higher than that with UCB (Supplementary Figure 2) . The use of PB or BM did not affect OS, relapse, or NRM (Supplementary Table 5 ).
DISCUSSION
In this nationwide retrospective study, we found that the survival rate in the UCB group was comparable to that in the RD/1AG-MM-GVH group regardless of the disease risk. The RD/1AG-MM-GVH group with an HLA-B mismatch showed significantly higher overall and NRM, whereas the RD/1AG-MM-GVH group with an HLA-A or HLA-DR mismatch showed an OS comparable to that in the UCB group. Neutrophil and platelet engraftment in the RD/1AG-MM-GVH group were significantly faster than those in the UCB group, whereas the incidence of acute or chronic GVHD in the RD/1AG-MM-GVH group was significantly higher. However, the incidence of acute or chronic GVHD in the RD/1AG-MM-GVH group with in vivo T-cell depletion was comparable to that in the UCB group, which translated into a better, but not significantly better, OS than that in the UCB group.
In Japan, unrelated BM donor coordination (from donor search to transplantation) takes a median of 4 months, whereas much less time is required for UCB or RD/1AG-MM-GVH transplantation if there is a candidate. This was reflected in the longer duration from diagnosis to transplantation in unrelated BM transplantation. 32 In contrast, UCB and RD/1AG-MM-GVH transplantation show a similar and shorter duration (Table 1 ; 7.9 months vs 7.6 months). Therefore, in cases where both UCB and RD/1AG-MM-GVH are available, donors should be chosen based on their advantages and disadvantages. Compared with UCB, the use of RD/1AG-MM-GVH has a great advantage in neutrophil and platelet engraftment, which is not inconsistent with a previous finding that engraftment in the UCB group was significantly delayed comparing with that in MUD. 33 This translated into a lower rate of death from graft failure or infection in the RD/1AG-MM-GVH group. However, these advantages were offset by a substantial increase in the incidence of acute and chronic GVHD in the RD/1AG-MM-GVH group. The risk of grade III-IV acute GVHD and extensive chronic GVHD in the RD/1AG-MM-GVH group was twice that in the UCB group. If UCB units containing adequate total nucleated cell doses (ex. 42.5 Â 10 7 /kg) are available, 34 the selection of UCB would be appropriate to avoid the risk of chronic GVHD. In contrast, RD/1AG-MM-GVH would be more appropriate when early neutrophil engraftment should be prioritized, such as for a patient with an active infectious disease at transplantation.
The high incidences of GVHD and GVHD-related death in the RD/1AG-MM-GVH group indicate the need for stronger immunosuppression to improve the clinical outcome. The use of T-cell depletion, mostly by ATG, was significantly associated with a lower incidence of grade III-IV acute GVHD and extensive chronic GVHD in the RD/1AG-MM-GVH group. Although this effect was not statistically significant, the RD/1AG-MM-GVH group with in vivo T-cell depletion showed lower overall and treatment-related mortality, which would outweigh a possible increased risk of relapse. These findings in our cohort suggest that ATG may be effective, and the addition of ATG in the RD/1AG-MM-GVH group should be assessed in a prospective study.
As shown in our previous study, 23 overall mortality in the RD/1AG-MM-GVH group involving an HLA-B mismatch was significantly higher than that in the RD/1AG-MM-GVH group with an HLA-A or -DR mismatch, probably because of an additional HLA-C antigen mismatch as expected from linkage disequilibrium between HLA-B and HLA-C and available data on HLA-C antigen. 23, 35 The incidence of grade III-IV acute GVHD in the HLA-B mismatch group was higher than that in the HLA-DR mismatch group, but was comparable to that in the HLA-A mismatch group. In addition, the incidence of death from GVHD was similar in the HLA-B and HLA-A/DR mismatch groups (data not shown). Therefore, the reason for the lower overall morality in the RD/1AG-MM-GVH group with an HLA-B mismatch remains unclear. However, the adverse effect of an HLA-B mismatch disappeared when in vivo T-cell depletion was used, which suggests that an immunological effect is involved in this mechanism.
This study has several limitations. First, in clinical practice in Japan, matching of HLA-DR is counted at a low resolution, as with HLA-A and HLA-B, whereas it is counted at a high resolution in the United States and Europe. To evaluate the impact of this difference, we divided patients in the UCB group with two antigen mismatches into two groups by using available HLA-DRB1 allele information: a group with two antigen mismatches with one additional HLA-DRB1 allele mismatch (n ¼ 609) and another group with two antigen mismatches without an additional HLA-DRB1 mismatch (n ¼ 295). We did not find a significant difference in OS between these two groups (P ¼ 0.758), which suggests that HLAmatching using HLA-DR antigen or allele information will not affect OS in the present study. Second, the findings in the present study are based on Asian cohort who received a 'single' UCB or RD/1AG-MM-GVH transplantation. Lighter body weight in Asian population than Caucasian population may make it easy to find a suitable single UCB unit that contains adequate total nucleated cell doses. In addition, as suggested by Oh et al., 36 limited heterogeneity of Japanese population may affect the outcomes of transplantation. Therefore, the findings should be externally validated in the non-Asian cohort or transplantation using double UCB units. Third, information on the dose and type of ATG was missing in two-third of the patients who received ATG. However, the available data showed that the median dose of thymoglobulin (2.5 mg/kg) or ATG-F (8 mg/kg) was equivalent to the dose that is widely used in our daily practice. Lastly, heterogeneous backgrounds may have resulted in a bias, although we tried to adjust for possible confounders by multivariate analyses. Lastly, the effect of multiple testing should be taken into account for the interpretation of secondary end points.
In conclusion, our findings suggest that both UCB and RD/ 1AG-MM-GVH are suitable as alternative donors for patients without an HLA-matched sibling or unrelated donor. However, the presence of an HLA-B-antigen mismatch in the GVH direction has an adverse effect on OS because of treatment-related complications. Neutrophil and platelet engraftment in the RD/1AG-MM-GVH group were significantly faster than those in the UCB group, whereas the incidence of acute and chronic GVHD in the RD/1AG-MM-GVH group was significantly higher, which translated into a high incidence of death from GVHD. Donor selection between UCB and RD/1AG-MM-GVH should be determined based on the presence of an HLA-B mismatch in RD/1AG-MM-GVH and from the risks and benefits derived from the risk of graft failure and infection in the UCB group and acute or chronic GVHD in the RD/1AG-MM-GVH group. Additional immune suppression using in vivo T-cell depletion may improve the clinical outcome in the RD/1AG-MM-GVH group by decreasing the incidences of GVHD and NRM and may also overcome the adverse effect of an HLA-B mismatch. This approach should be assessed in a prospective study.
